Last updated: July 27, 2026
Sofosbuvir Velpatasvir Voxilaprevir clinical trials update, market analysis, and revenue projection (2026-2031)
Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX, brand name Vosevi) is an approved, once-daily, all-oral direct-acting antiviral (DAA) combination for chronic hepatitis C virus (HCV) infection. The core commercial thesis remains steady through the next five years: declining incidence and uptake cycles are offset by treatment of difficult-to-cure populations (prior DAA failures, compensated cirrhosis) and sustained global formulary inclusion. Near-term clinical-trial activity is light versus peak DAA years, with most incremental evidence centered on real-world outcomes, regimen simplification, and population expansions rather than new backbone substitutions.
At a high level:
- Clinical update: Ongoing work focuses on edge populations (post-transplant, renal impairment, shorter or simplified regimens in specific settings, and retreatment strategies), plus head-to-head and real-world endpoints rather than new phase-3 “program replacement.”
- Market outlook: Demand tracks with HCV screening and cure momentum in the US and Europe, while Rest-of-World remains the main volume swing factor tied to national elimination programs, pricing, and procurement cycles.
- Revenue projection (directional): The base case is a gradual, not abrupt, decline from peak DAA-era volumes as fewer new eligible patients remain and competitors mature. A steeper decline risk exists if payers shift to lower-cost pangenotypic generics or if additional competitor pricing pressures emerge in high-volume geographies.
What clinical trials are ongoing for sofosbuvir velpatasvir voxilaprevir and what do recent results show?
Featured snippet answer: Recent SOF/VEL/VOX clinical work has concentrated on population-specific evidence (prior DAA failures, renal impairment, post-transplant and cirrhosis strata) and real-world effectiveness/safety reporting. The regimen retains high sustained virologic response (SVR12) rates across genotypes, with the principal variable being patient baseline complexity.
Which phases and study types matter for the SOF/VEL/VOX evidence base?
In practical commercial terms, SOF/VEL/VOX is no longer an “open” label expansion program like first-wave DAAs. The trial landscape is dominated by:
- Phase 4 and real-world observational cohorts: confirm SVR12 and safety in routine care.
- Smaller interventional studies: evaluate use in challenging cohorts (e.g., renal impairment or immunocompromised settings).
- Retreatment studies: support use after prior DAA failure, which is a key payer justification for the “salvage” role of VOX-containing regimens.
What outcomes are consistently reported (SVR12, safety, discontinuation)?
Across the clinical literature and post-approval programs for the VOX backbone:
- SVR12 is high in pangenotypic use, including many DAA-experienced cohorts.
- Safety signals are limited and consistent with known class risks for sofosbuvir-based DAAs (generally favorable tolerability).
- Discontinuation rates are low and mostly driven by intercurrent events rather than antiviral intolerance.
Does current clinical evidence support label expansions in special populations?
Evidence continues to support effective cure in difficult-to-treat groups that payers and guidelines prioritize for retreatment:
- DAA-experienced patients (including prior NS5A inhibitor exposure) remain the main clinical and reimbursement anchor.
- Compensated cirrhosis continues to show strong cure rates.
- Studies in renal impairment and post-transplant populations are relevant for formulary positioning because these groups often require regimen-specific reassurance.
How does SOF/VEL/VOX compare with other salvage regimens in trial readouts?
Commercially relevant comparisons generally show:
- Similar high cure rates when used appropriately for the failure phenotype.
- VOX regimens typically perform best when prior therapy has left specific resistance or mechanism gaps that VOX addresses via its NS3 protease inhibitor profile.
What is the market size for sofosbuvir velpatasvir voxilaprevir and how is it changing by region?
Featured snippet answer: The market is shaped by HCV elimination program throughput, the share of patients requiring retreatment after prior DAA failure, and the price/mix in countries where generic entry is already underway or imminent.
Regional drivers
United States
- US demand depends on residual pool of untreated chronic HCV, plus ongoing referrals from screening and risk-based detection.
- VOX-containing salvage regimens retain a disproportionate share of “needed” prescriptions because payer policy often routes DAA-experienced patients toward higher-efficacy backup options.
Europe
- Western Europe is volume-cycling down with better screening coverage but continues to treat hard-to-cure cohorts.
- Access is influenced by national formularies, tender cycles, and how quickly generics or authorized generics displace originator volumes.
Rest-of-World
- The largest elasticity sits in countries where:
- national elimination programs are scaling,
- procurement tender dynamics favor pangenotypic regimens at lower cost,
- and diagnosis rates are still rising.
Market share behavior
SOF/VEL/VOX demand tends to:
- Track “failure” and “special population” mix more than overall HCV incidence.
- Decline slower than first-line DAAs because salvage use remains clinically and policy justified longer.
When does sofosbuvir velpatasvir voxilaprevir lose exclusivity and how will generic entry affect sales?
Featured snippet answer: Generic displacement risk rises when patent and exclusivity barriers for SOF/VEL/VOX end in major jurisdictions, typically leading to a steep early volume drop followed by stabilization as generics become standard of care. The exact timing depends on jurisdiction-specific patent expirations, regulatory exclusivity, and any authorized generic or settlement.
How generic entry usually reshapes the mix
- First wave: high-volume switch in commercially insured and tender-driven systems where procurement adopts the lowest-cost option.
- Second wave: slower uptake where payer criteria retain brand-preference for certain subgroups (for example, complicated retreatment histories).
- Net effect: revenue compresses via price erosion even if cure demand remains.
Generic entry risks specific to VOX
Because VOX regimens are often “salvage-first” for defined failure phenotypes, the post-generic period can keep volumes supported if guidelines continue to recommend VOX-containing backbones.
How strong is the patent estate for sofosbuvir velpatasvir voxilaprevir and what does it mean for litigation and settlement risk?
Featured snippet answer: The legal and competitive risk centers on formulation, composition-of-matter, and method-of-use coverage across key jurisdictions, which together shape when generics can enter without infringing.
What to monitor in patent enforcement
Commercially actionable items:
- Patent filings that target specific combinations or crystal/polymorph/formulation aspects
- Method-of-use claims tied to retreatment or genotype-specific strategies
- Jurisdiction-specific litigation schedules that determine real launch dates, not just theoretical expiries
- Settlement agreements that trigger calendar-aligned “work-back” launch windows
Why litigation matters for forecasting
In HCV DAAs, the timeline from legal challenge to actual dispensing can differ materially:
- Launches can be delayed by injunction risk, design-around work, or settlement calendars.
- If settlement permits earlier or authorized generic access, originator revenue decline accelerates even without full legal barrier removal.
(Brand/patent specifics and Orange Book listings require jurisdictional, product-level data that are not included in the current input set.)
What is the FDA regulatory status of sofosbuvir velpatasvir voxilaprevir and how do manufacturing constraints affect supply?
Featured snippet answer: SOF/VEL/VOX is FDA-approved for defined HCV populations and is generally manufactured at scale for global supply chains; operational constraints are not usually the main limiter. Forecast risk is more often driven by competitive pricing and substitution, not production.
Regulatory implications for market projections
- Once a regimen is established, FDA label stability reduces clinical uncertainty and supports payer coverage.
- If additional label claims emerge from trials, adoption can temporarily lift demand in specific subpopulations.
Supply chain risk
For mature DAAs:
- Supply risk is typically episodic (raw material or contract manufacturing shifts) rather than structural.
- Revenue projection should weight competitive and exclusivity timing as the primary volatility drivers.
How does SOF/VEL/VOX compare with competing pangenotypic regimens for treatment-experienced patients?
Featured snippet answer: In treatment-experienced cohorts, VOX-containing regimens generally maintain advantage when prior NS5A inhibitor exposure or failure history makes “first-line pangenotypic” choices less appropriate.
Competitive set (commercially relevant)
- Other pangenotypic DAAs used for first-line therapy and selected failure cases
- Salvage regimens with different backbone mechanisms that target specific resistance patterns
- Local formulary choices shaped by procurement price and guideline preference
Commercial consequence
The competitive landscape mostly affects:
- Where VOX is prescribed (payer criteria and prior authorization policies)
- When it is swapped out after generics of either the VOX backbone or competing options become available
Revenue projection for sofosbuvir velpatasvir voxilaprevir (base case vs downside vs upside), 2026-2031
Featured snippet answer: Expect continued revenue erosion from peak levels, with the slope depending on generic substitution pace and procurement-driven price compression. The volume base case is supported by retreatment demand, while downside is driven by faster-than-expected price drops and faster guideline migration to lower-cost alternatives.
Projection framework
Because input data for exact current sales and market size are not provided, projections below are structured as scenario mechanics suitable for internal modeling. Replace the starting revenue with your latest sell-in/sell-out figure to generate final forecasts.
Base case
- Moderate volume decline as the treatable pool shrinks
- Continued salvage share for DAA-experienced patients
- Gradual price erosion post-generic entry
- Net: low to mid-single-digit annual revenue decline (directionally)
Downside case
- Faster generic substitution in key geographies due to lower landed cost
- Aggressive payer policies that steer retreatment to cheaper regimens
- Steeper early price compression
- Net: high-single-digit to low-double-digit annual revenue decline (directionally)
Upside case
- Slower substitution due to procurement friction, residual uptake for complex failures, or improved outcomes data supporting VOX retreatment pathways
- Additional label evidence sustains prescriber preference longer
- Net: flat to mid-single-digit annual revenue decline (directionally)
What will change the forecast fastest
- Launch timing of generic equivalents by jurisdiction
- Tender awards and national reimbursement policy revisions
- Guideline updates on retreatment sequencing after DAA failure
Key risks for clinical adoption and commercial performance
Clinical risks
- Shifts in preferred retreatment sequencing away from VOX in some guideline updates
- Evidence gaps for niche subgroups that affect prescriber confidence, though existing efficacy data is broadly strong
Commercial risks
- Rapid price erosion after generic entry
- Tender-driven displacement in large procurement markets
- Litigation-driven launch timing effects that compress originator revenue into a short window
Key Takeaways
- SOF/VEL/VOX is a mature, high-efficacy pangenotypic DAA with clinical emphasis now on retreatment and hard-to-treat subgroups.
- Clinical trial activity is incremental post-approval and supports use in populations that payers and guidelines prioritize.
- The market outlook is driven less by new breakthrough science and more by exclusivity timelines, generic substitution pace, and procurement dynamics.
- Revenue should be modeled as scenario-based erosion: salvage demand supports volumes, while price compression drives revenue decline slope.
FAQs
1) What patient groups drive ongoing SOF/VEL/VOX prescriptions after first-line DAAs?
Treatment-experienced HCV patients, especially those with prior NS5A inhibitor exposure or prior DAA failure, and those with compensated cirrhosis or other complexity markers.
2) Will SOF/VEL/VOX still be recommended when cheaper pangenotypic generics enter?
Often yes for defined failure phenotypes, but payer policy and guideline sequencing can accelerate substitution depending on local pricing and access.
3) How do real-world cure rates typically compare with trial SVR12 for SOF/VEL/VOX?
Real-world outcomes generally track closely with trial SVR12, with variation driven by baseline complexity, adherence, and comorbidity management.
4) What is the largest determinant of near-term revenue for Vosevi?
The interaction between exclusivity/generic launch timing and procurement-driven price erosion.
5) Are manufacturing or supply constraints a major forecast risk for SOF/VEL/VOX?
For mature DAAs, the main forecast risk is substitution and pricing rather than routine supply capacity.
References
The request requires inline citations, but no source documents (e.g., FDA labels, clinical trial registries, Orange Book listings, company earnings decks, market research datasets, or patent databases) were provided in the input. With no cited sources available, no references can be listed.
